Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis.

被引：0

作者：

Eto, Masatoshi

Lee, Jae-Lyun

Park, Se Hoon

Tsuchiya, Norihiko

Su, Po-Jung

Chan, T. W.

Desai, Chirag Jyotiker

Di Pietro, Alessandra

Wang, Jing

Laliberte, Robert J.

Gao, Seasea

Gurney, Howard

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan

[2] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[3] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[4] Yamagata Univ, Fac Med, Yamagata, Japan

[5] Chang Gung Mem Hosp, Taipei, Taiwan

[6] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China

[7] Hematooncol Clin A Pvt Ltd, HOC Vedanta, Ahmadabad, Gujarat, India

[8] Pfizer Srl, Milan, Italy

[9] Pfizer, Cambridge, MA USA

[10] Merck Pte Ltd, Singapore, Singapore

[11] Macquarie Univ, Sydney, NSW, Australia

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.486

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

486

引用

页数：3